Target intelligence / Profile preview

Mitogen-activated protein kinase 3/Mitogen-activated protein kinase 1 (MAPK3/MAPK1)

Target
MAPK3/MAPK1
Molecular classification
Enzyme, Kinase, Serine/threonine-protein kinase
01

Overview

Mitogen-activated protein kinase 3 (MAPK3/ERK1) and mitogen-activated protein kinase 1 (MAPK1/ERK2) are highly homologous serine/threonine-protein kinases that function as the terminal effectors of the canonical RAS-RAF-MEK-ERK signaling cascade. Upon activation by upstream dual-specificity MEK1/2 kinases, ERK1/2 phosphorylate a vast array of cytoplasmic and nuclear substrates, including transcription factors like Elk-1 and c-Fos, thereby regulating critical cellular processes such as proliferation, differentiation, survival, and cell cycle progression. Dysregulation and hyperactivation of the MAPK3/MAPK1 pathway are implicated in approximately 40% of human cancers, particularly those driven by oncogenic mutations in upstream regulators like KRAS, NRAS, and BRAF.\n\nConsequently, MAPK3/MAPK1 represents a highly attractive therapeutic target in oncology, especially for overcoming acquired resistance to upstream RAF and MEK inhibitors. Several small-molecule ERK1/2 inhibitors, such as ulixertinib, temuterkib, and GDC-0994, are currently undergoing clinical evaluation. However, targeting these kinases presents significant therapeutic challenges, including dose-limiting toxicities such as severe dermatologic rashes, gastrointestinal issues, and retinopathy, as well as the rapid emergence of drug resistance through compensatory bypass pathways like the PI3K/AKT/mTOR axis.

Other names
Extracellular signal-regulated kinase 1/2ERK1/2p44/42 MAPKMitogen-activated protein kinase 3/1MAPK3/1ERK1ERK2MAPK3MAPK1
02

Mechanism of action

ERK1/2 inhibitor

03

Biological functions

Signal transductionCell proliferationCell cycleApoptosisCell differentiationCell survivalGene expression regulation
04

Disease associations

CancerInflammationNeurodegenerative diseaseCardiovascular disease
05

Safety considerations

Dermatologic adverse events (acneiform rash, maculopapular rash, pruritus)Gastrointestinal toxicity (diarrhea, nausea, vomiting)FatigueERK inhibitor-associated retinopathy (ERKAR)QT interval prolongationMyocardial dysfunction (decreased left ventricular ejection fraction)Therapeutic resistance via bypass pathway activation (e.g., PI3K/AKT/mTORC1)
06

Interacting drugs

7 more in the full profile.

07

Biomarkers

Phospho-ERK1/2 (p-ERK1/2)Phospho-RSK (p-RSK)DUSP6 expressionBRAF V600E mutationKRAS mutationNRAS mutation

Beyond the preview

Go deeper on Mitogen-activated protein kinase 3/Mitogen-activated protein kinase 1 (MAPK3/MAPK1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mitogen-activated protein kinase 3/Mitogen-activated protein kinase 1 (MAPK3/MAPK1).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call